Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 17/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009157 | 0.91 | FBP1 (0.72) | FBP1 | |
| Carbutamide SCHEMBL4078762 | 0.83 | ALDH1A1 (0.76) | FBP1CYP2C9ALDH1A1LMNAALB | |
| Carbutamide SCHEMBL49231 | 0.83 | ALDH1A1 (0.76) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL184964 | 0.83 | CYP2C9 (0.76) | FBP1CYP2C9ALDH1A1LMNAALB | |
| Methyl Alcohol SCHEMBL28260710 | 0.82 | CYP2C9 (0.74) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL9303571 | 0.81 | FBP1 (0.70) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL922624 | 0.80 | PRMT1 (0.62) | FBP1ALDH1A1LMNATSHR | |
| SCHEMBL5264294 | 0.80 | CYP2C9 (0.55) | FBP1CYP2C9 | |
| SCHEMBL11049679 | 0.79 | CYP2C9 (0.69) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL27804679 | 0.79 | TSHR (0.58) | FBP1ALDH1A1LMNATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | claimed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | claimed |
| US-8329217-B2 | Dual controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2012-12-11 | — | — | US | claimed |
| US-8227465-B2 | Combination of triazine derivatives and insulin secretion stimulators | POXEL SAS (FR) | 2012-07-24 | — | — | US | claimed |
| US-20100233255-A1 | COMBINATION OF TRAZINE DERIVATIVES AND INSULIN SECRETION STIMULATORS | POXEL SAS (FR) | 2010-09-16 | — | — | US | claimed |
| US-20090131404-A1 | Combinations | ALLISON MALCOLM | 2009-05-21 | — | — | US | claimed |
| EP-1931359-A4 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | ELIXIR PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1980249-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | Novartis AG (CH) | 2008-10-15 | — | — | EP | claimed |
| EP-1971339-A2 | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SECRETION STIMULATORS | Merck Patent GmbH (DE) | 2008-09-24 | — | — | EP | claimed |
| EP-1351683-B1 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | NOVARTIS AG (CH) | 2008-06-25 | — | — | EP | claimed |
| US-20040002519-A1 | Combination of organic compounds | DAMON ROBERT EDSON (US) | 2004-01-01 | — | — | US | claimed |
| EP-1351683-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | Novartis AG (CH) | 2003-10-15 | — | — | EP | claimed |
| WO-2003080070-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITTOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2003-10-02 | — | — | WO | claimed |
| WO-2002015933-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-6329404-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | claimed |
| US-6303640-B1 | ADMINISTERING OXAZOLE OR THIAZOLE DERIVATIVE COMPOUND FOR REDUCING SIDE EFFECTS OF DIABETIC THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| US-6211205-B1 | ANTIDIABETIC AGENTS THAT ENHANCE INSULIN SECRETION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6150383-A | COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131404-A1 | Combinations | HMGCR, ACE, PCSK9 | FBP1 449/4885CYP2C9 220/4885ALDH1A1 1703/4885 |
| US-20100233255-A1 | COMBINATION OF TRAZINE DERIVATIVES AND INSULIN SECRETION STIMULATORS | IAPP, GPR119, INSR | FBP1 1391/4885CYP2C9 4562/4885ALDH1A1 4782/4885 |
| US-20040002519-A1 | Combination of organic compounds | HMGCR, SRD5A2, HSD17B7 | FBP1 524/4885CYP2C9 351/4885ALDH1A1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.